To the Editor: De Menezes and colleagues1 report increasing use of shave biopsy for melanoma diagnosis in association with significant rates of base transection. They cite a wide range of base transection rates in the literature (7–68%), giving pause for thought: what is at play here besides the shave biopsy itself? This is an important question, as the incidence of invasive melanoma rose significantly over the study period along with a doubling of the frequency of shave biopsy. Particularly in Queensland, dubiously honoured with the title of “melanoma capital of the world,” we must be cautious about dismissing this efficient and low cost procedure.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.